ALC · Earnings event · Q2 2026 · recent
Alcon (ALC) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.84 vs estimate $0.76 (+11.2%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.76 | $0.84 | +11.2% |
| Revenue | — | — | — |
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated ALC Buy (Wait) at 5.3/10. After the Q2 2026 report, the verdict moved to Hold at 5.2/10.
Healthcare context
ALC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $35.89B
- P/E (fwd)
- 18.7
- P/E (ttm)
- 56.7
- 52-week range
- $61.84–$90.41
- Off 52-week high
- 17.9%
- RSI (14)
- 73
- Volume vs avg
- 0.51×
- Engine score
- 5.4/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.